SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · Real-Time Price · USD
3.880
+0.620 (19.02%)
At close: Nov 1, 2024, 4:00 PM
3.620
-0.260 (-6.70%)
After-hours: Nov 1, 2024, 5:27 PM EDT
19.02%
Market Cap 35.81M
Revenue (ttm) 2.78M
Net Income (ttm) -40.32M
Shares Out 9.23M
EPS (ttm) -5.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,349
Open 3.375
Previous Close 3.260
Day's Range 3.340 - 3.980
52-Week Range 2.160 - 10.000
Beta 0.70
Analysts Strong Buy
Price Target 12.40 (+219.59%)
Earnings Date Nov 11, 2024

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 57
Stock Exchange NASDAQ
Ticker Symbol SABS
Full Company Profile

Financial Performance

In 2023, SAB Biotherapeutics's revenue was $2.24 million, a decrease of -90.63% compared to the previous year's $23.90 million. Losses were -$42.19 million, 125.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price forecast is $12.4, which is an increase of 219.59% from the latest price.

Price Target
$12.4
(219.59% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymoc...

7 weeks ago - GlobeNewsWire

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymoc...

2 months ago - GlobeNewsWire

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“...

3 months ago - GlobeNewsWire

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a ...

3 months ago - GlobeNewsWire

SAB BIO Appoints Lucy To as Chief Financial Officer

MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is de...

3 months ago - GlobeNewsWire

SAb Biotherapeutics Rebrands as SAB BIO

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) ...

4 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human ...

4 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human a...

5 months ago - GlobeNewsWire

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Com...

5 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is devel...

5 months ago - GlobeNewsWire

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human a...

6 months ago - GlobeNewsWire

SAB Biotherapeutics Provides SAB-142 Trial Update

MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platfo...

7 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at INNODIA Annual Meeting

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platfo...

7 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...

7 months ago - GlobeNewsWire

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 20...

7 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform...

7 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platfor...

9 months ago - GlobeNewsWire

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform ...

9 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Executive Leadership Change

SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform ...

9 months ago - GlobeNewsWire

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developin...

10 months ago - GlobeNewsWire

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human a...

10 months ago - GlobeNewsWire

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG)

1 year ago - GlobeNewsWire

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human...

1 year ago - GlobeNewsWire

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ: SABS), a clinical stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-h...

1 year ago - GlobeNewsWire

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors

1 year ago - GlobeNewsWire